Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Sponsor
Beijing Friendship Hospital
Study ID
NCT04258644
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of gastric cancer.

Key Dates

Start date
Mar 1, 2020
Status verified
Feb 2020
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1
    Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1\~21, 250 mg, po qd Paclitaxel-albumin：D1\&D8, 100～120 mg/m2 S-1：D1\~14, 60mg bid

Primary Outcome Measure

R0 resection rate [ Time Frame: 3 years ]

Central Contacts

Related Studies